股静脉血栓吃利伐沙班要多久？

It takes about 6 months for patients with femoral vein thrombosis, and the specific time should be determined according to the patient's condition. Studies show that the thrombus resolution rates of rivaroxaban at 1, 3, and 6 months are 71.8%, 76.9%, and 87.2% respectively.

femoral vein thrombosis

The formation of femoral vein thrombosis is generally related to long-term lack of exercise, long-term smoking, excessive obesity, hypercoagulable state in the body, or various chronic diseases such as heart failure and diabetes. The main clinical feature of thrombosis limited to the femoral vein is thigh swelling and pain, and the swelling of the lower limbs is often not serious.

Rivaroxaban

When patients with femoral vein thrombosis are treated with rivaroxaban, they need to be treated for about 6 months, or even longer. The specific time needs to be determined according to the condition of the disease. After 6 months of treatment in most patients, the resolution rate of femoral vein thrombosis was 87.2%.

Rivaroxaban’s mechanism of action

The main mechanism of action is to directly inhibit factor Xa and tissue thrombin synthesis to prevent thrombosis.

Coagulation factor

Rivaroxaban has obvious effects in the treatment of patients with venous thromboembolism. It will not inhibit the patient's coagulation function and will not have a major impact on the patient's cardiac function.

Advantages of Rivaroxaban Treatment

Rivaroxaban is a small molecule substance. After oral administration, it inhibits the amount of factor Xa and FXa without affecting serine protease. It can exert a significant anticoagulant effect without any co-factors.

The bioavailability of this drug can be as high as 85%-100%, and the blood concentration can reach the peak 2-4 hours after oral administration. The drug has rapid effects and a short half-life, so no monitoring is required.

Rivaroxaban is mainly used for the acute or long-term treatment of deep vein thrombosis to prevent venous thrombosis after major surgery. It is suitable for all people. The drug takes effect quickly and has a lower risk of bleeding than warfarin.

In addition, the metabolites of rivaroxaban can be excreted in urine and feces and will not remain in the body, making it extremely safe.

References

1. [1] Wang Kejing, Wang Xi, Wang Yunyun, Qiao Wei. Research progress on non-vitamin K antagonist oral anticoagulants in the treatment of left ventricular thrombus [J]. Journal of Cardiopulmonary and Vascular Diseases, 2022, 41(03): 317-320.

Recommended related articles: